Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure

Blood. 2004 Mar 1;103(5):1968. doi: 10.1182/blood-2003-10-3612.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Aminoglycosides / pharmacology*
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD / biosynthesis
  • Antigens, Differentiation, Myelomonocytic / biosynthesis
  • Child
  • Child, Preschool
  • Female
  • Gemtuzumab
  • Hematopoietic Stem Cell Transplantation*
  • Hepatic Veno-Occlusive Disease / prevention & control*
  • Humans
  • Infant
  • Leukemia, Myeloid, Acute / drug therapy
  • Male
  • Platelet Aggregation Inhibitors / pharmacology
  • Polydeoxyribonucleotides / pharmacology*
  • Recurrence
  • Regression Analysis
  • Remission Induction
  • Sialic Acid Binding Ig-like Lectin 3

Substances

  • Aminoglycosides
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • CD33 protein, human
  • Platelet Aggregation Inhibitors
  • Polydeoxyribonucleotides
  • Sialic Acid Binding Ig-like Lectin 3
  • defibrotide
  • Gemtuzumab